Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells

• Autorzy: Hualg H. , Li T. , Chen M. , Li X.
• Języki publikacji: EN

Abstrakty

EN

Adjuvant chemotherapy has become the frequently adopted standard therapeutic approach for non-small cell lung cancer (NSCLC). However, the development of multidrug resistance (MDR) is a major obstacle contributing to the failure of chemotherapy. This study aimed to identify genes associated with MDR development that predict tumor response to chemotherapy in NSCLC. In the present study, a multidrug-resistant NSCLC cell sub-line, A549/MDR, was established from the A549/DDP cell line and characterized. The resistance index (RI) of this subline was calculated according to the IC50 of A549/MDR relative to the parental A549/DDP cells. The gene expression profiles of A549/DDP and A549/MDR were obtained using an oligonucleotide microarray (Agilent SureHyb microarray chip). The microarray results were validated by qRT-PCR and selected genes were analyzed by in vitro loss-of-function experiments. Gene expression profiling identified 921 differentially expressed genes (DEGs) according to the selection criteria, in which 541 genes were upregulated and 380 genes were downregulated in A549/MDR compared with A549/DDP cells. We found that these DEGs are involved in diverse biological processes, including ribonucleoprotein complex, drug metabolism, the Hippo signaling pathway and transcriptional misregulation. NOLC1, as one of the identified DEGs, was confirmed to be overexpressed in A549/MDR cells and its knockdown significantly enhanced the drug sensitivity of A549/MDR cells in response to multidrug treatment. Furthermore, knockdown of NOLC1 downregulated the expression levels of drug resistance-associated molecules (LRP and MDR1) in A549/MDR cells. These findings provide a new and comprehensive expression profile of MDR in NSCLC cells. Identification and validation of NOLC1 might be a promising therapeutic strategy for the management of MDR of NSCLC patients.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2018
• Tom: 23
• Opis fizyczny: p.1-13,fig.,ref.

Twórcy

autor

Hualg H.

• Department of Respiratory Diseases, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan, China

autor

Li T.

• Department of Respiratory Diseases, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan, China

autor

Chen M.

• Department of Respiratory Diseases, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan, China

autor

Li X.

• Department of Respiratory Diseases, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan, China

Bibliografia

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
• 2. Sakamoto J, Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakajima D, et al. Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer. Int J Clin Oncol. 2014;19(1):50–6.
• 3. Huang H, Liu J, Meng Q, Niu G. Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively. Int J Clin Exp Pathol. 2015;8(9):11537–42.
• 4. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.
• 5. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.
• 6. Cheng W, Nie J, Gao N, Liu G, Tao W, Xiao X, et al. A multifunctional nanoplatform against multidrug resistant cancer: merging the best of targeted chemo/gene/photothermal therapy. Adv Funct Mater. 2017;27(45):1704135.
• 7. Sonneveld P, Segeren CM. Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment. Eur J Cancer. 2003;39(1):9–18.
• 8. An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7(1):38–51.
• 9. Sun M, Yang C, Zheng J, Wang M, Chen M, Le DQS, et al. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Acta Biomater. 2015;28: 171–82.
• 10. Pang J, Shi Q, Liu Z, He J, Liu H, Lin P, et al. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression. Haematologica. 2017;102(7):1273–80.
• 11. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.
• 12. Zhang K, Li M, Huang H, Li L, Yang J, Feng L, et al. Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/beta-catenin signaling. Oncotarget. 2017;8(70):115803–16.
• 13. Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018;32(1):8–28.
• 14. Dong H, Wang C, Lu S, Yu C, Huang L, Feng W, et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease. Biomarkers. 2016;21(2):129–37.
• 15. Yao Q, Gutierrez DC, Hoang NH, Kim D, Wang R, Hobbs C, et al. Efficient codelivery of paclitaxel and curcumin by novel bottlebrush copolymer-based micelles. Mol Pharm. 2017;14(7):2378–89.
• 16. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumour samples for p-glycoprotein and multidrug resistance-associated protein. Eur J Cancer. 1996;32(6):1024–33.
• 17. Vert A, Castro J, Ribo M, Vilanova M, Benito A. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. Onco Targets Ther. 2018;11:221–37.
• 18. Wang YW, Zhang W, Ma R. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data. Oncol Rep. 2018;39(3):1003–10.
• 19. Zhao YP, Chen G, Feng B, Zhang TP, Ma EL, Wu YD. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer. Chin Med J. 2007;120(20):1743–52.
• 20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.
• 21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
• 22. Wang P, Chen D, Ma H, Li Y. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017;8(48):84086.
• 23. Arriagada R, Auperin A, Burdett S, Higgins JPT, Johnson DH, Chevalier TL, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267.
• 24. Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, et al. Expression of multidrug resistance-associated protein1, Pglycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer. 2002;86(10):1578–85.
• 25. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008;58(6):261–4.
• 26. Hung TH, Hsu SC, Cheng CY, Choo KB, Tseng CP, Chen TC, et al. Wnt5A regulates ABCB1 expression in multidrugresistant cancer cells through activation of the non-canonical PKA/β-catenin pathway. Oncotarget. 2014;5(23):12273–90.
• 27. Meier UT, Blobel G. A nuclear localization signal binding protein in the nucleolus. J Cell Biol. 1990;111(6 Pt 1):2235–45.
• 28. Meier UT, Blobel G. Nopp140 shuttles on tracks between nucleolus and cytoplasm. Cell. 1992;70(1):127–38.
• 29. Yao Y, Fan Y, Wu J, Wan H, Wang J, Lam S, et al. Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis. Biochem Biophys Res Commun. 2012;423(3):613–9.
• 30. Krastev DB, Slabicki M, Paszkowskirogacz M, Hubner NC, Junqueira M, Shevchenko A, et al. A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Nat Cell Biol. 2011;13(7):809.
• 31. Chen HK, Yeh NH. The nucleolar phosphoprotein P130 is a GTPase/ATPase with intrinsic property to form large complexes triggered by F- and Mg2+. Biochem Biophys Res Commun. 1997;230(2):370.
• 32. Pai CY, Yeh NH. Cell proliferation-dependent expression of two isoforms of the nucleolar phosphoprotein p130. Biochem Biophys Res Commun. 1996;221(3):581–7.
• 33. Pai CY, Chen HK, Sheu HL, Yeh NH. Cell-cycle-dependent alterations of a highly phosphorylated nucleolar protein p130 are associated with nucleologenesis. J Cell Sci. 1995;108(Pt 5):1911–20.
• 34. Hwang YC, Lu TY, Huang DY, Kuo YS, Kao CF, Yeh NH, et al. NOLC1, an enhancer of nasopharyngeal carcinoma progression, is essential for TP53 to regulate MDM2 expression. Am J Pathol. 2009;175(1):342–54.
• 35. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 1999;59(14):3505–11.
• 36. Meschini S, Marra M, Calcabrini A, Monti E, Gariboldi M, Dolfini E, et al. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol in Vitro. 2002;16(4):389–98.
• 37. Bhardwaj M, Cho HJ, Paul S, Jakhar R, Khan I, Lee SJ, et al. Vitexin induces apoptosis by suppressing autophagy in multidrug resistant colorectal cancer cells. Oncotarget. 2018;9(3):3278–91.

Identyfikatory

DOI

10.1186/s11658-018-0119-8